نتایج جستجو برای: dmard therapy

تعداد نتایج: 654381  

2012
Christopher John Edwards Jennifer Campbell Tjeerd van Staa Nigel K Arden

OBJECTIVES To describe current disease-modifying antirheumatic drugs (DMARDs) prescription in rheumatoid arthritis (RA) with reference to best practice and to identify temporal and regional trends in the UK. DESIGN Descriptive, register-based cohort study. PARTICIPANTS Permanently registered patients aged ≥18 years with a recorded diagnosis of RA between 1 January 1995 and 31 March 2010 and...

Journal: :Arthritis care & research 2011
Vivian K Kawai Carlos G Grijalva Patrick G Arbogast Jeffrey R Curtis Daniel H Solomon Elizabeth Delzell Lang Chen Rita Ouellet-Hellstrom Lisa Herrinton Liyan Liu Edward F Mitchel C Michael Stein Marie R Griffin

Objective. We hypothesized that initiation of a new disease-modifying antirheumatic drug (DMARD) for treatment of rheumatoid arthritis (RA) would decrease the use of corticosteroids, nonsteroidal antiinflammatory drugs (NSAIDs), and narcotics.Methods. Using administrative databases, we assembled 4 retrospective cohorts of RA patients (1998-2005) and identified 5 groups initiating DMARD regimens...

2016
Juergen Rech Axel J Hueber Stephanie Finzel Matthias Englbrecht Judith Haschka Bernhard Manger Arnd Kleyer Michaela Reiser Jayme Fogagnolo Cobra Camille Figueiredo Hans-Peter Tony Stefan Kleinert Joerg Wendler Florian Schuch Monika Ronneberger Martin Feuchtenberger Martin Fleck Karin Manger Wolfgang Ochs Matthias Schmitt-Haendle Hanns-Martin Lorenz Hubert Nuesslein Rieke Alten Joerg Henes Klaus Krueger Georg Schett

OBJECTIVE To analyse the role of multibiomarker disease activity (MBDA) score in predicting disease relapses in patients with rheumatoid arthritis (RA) in sustained remission who tapered disease modifying antirheumatic drug (DMARD) therapy in RETRO, a prospective randomised controlled trial. METHODS MBDA scores (scale 1-100) were determined based on 12 inflammation markers in baseline serum s...

Journal: :Modern rheumatology 2011
Masaaki Mori Syuji Takei Tomoyuki Imagawa Hiroyuki Imanaka Yasuhito Nerome Rumiko Kurosawa Yoshifumi Kawano Shumpei Yokota Noriko Sugiyama Hirotoshi Yuasa Tracey Fletcher Joseph S Wajdula

Efficacy, safety, and pharmacokinetics results from 4 studies-3 open-label (OL) and 1 randomized double-blind (DB)-have provided data for approval of etanercept for treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory juvenile idiopathic arthritis (JIA) in Japan. Results from the 3 shorter-term (2 OL and 1 DB) studies are reported here. Subjects (4-17 years) enrolled in the OL ...

2014
George W. Reed Katherine Leung Ronald G. Rossetti Susan VanBuskirk John T. Sharp Robert B. Zurier

Objective. To determine whether a combination of borage seed oil rich in gamma linolenic acid (GLA) and fish oil rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is superior to either oil alone for treatment of rheumatoid arthritis (RA). Methods. Patients were randomized into a double-blind, 18-month trial. Mixed effects models compared trends over time in disease activity mea...

2016
Leslie R. Harrold George W. Reed Joel M. Kremer Jeffrey R. Curtis Daniel H. Solomon Marc C. Hochberg Arthur Kavanaugh Katherine C. Saunders Ying Shan Tanya M. Spruill Dimitrios A. Pappas Jeffrey D. Greenberg

BACKGROUND Factors associated with care concordant with the American College of Rheumatology (ACR) recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) are unknown. METHODS We identified a national cohort of biologic-naive patients with RA with visits between December 2008 and February 2013. Treatment acceleration (initiation or dose escal...

2016
Cheryl Barnabe Bonnie Healy Andrew Portolesi Gilaad G. Kaplan Brenda Hemmelgarn Charles Weaselhead

BACKGROUND Uncontrolled disease activity in inflammatory diseases of the joints, skin and bowel leads to morbidity and disability. Disease-modifying therapies are widely used to suppress this disease activity, but cost-coverage is variable. For Treaty First Nations and Inuit people in Canada without alternative private or public health insurance, cost-coverage for disease-modifying therapy is p...

Journal: :Reumatizam 2010
Srdan Novak

Disease activity assessment is a cornerstone of monitoring rheumatoid arthritis (RA) development and guidance for rituximab treatment. Beside clinical signs and symptoms biomarkers (RF and anti-CCP) are important early predictors of response to therapy and they can predict disease development. Autoantibody (RF and anti-CCP) seropositivity has been associated with positive response to rituximab ...

Journal: :Phytotherapy research : PTR 2012
Tamer A Gheita Sanaa A Kenawy

The constituents of Nigella sativa modulate the immune system. The aim of the present work was to study the effectiveness of Nigella sativa oil in RA patients. Data from 40 female RA patients diagnosed according to the 2010 ACR/EULAR were analysed and discussed. The patients took two placebo (starch filled) capsules daily for 1 month. This was followed by a month of Nigella sativa oil capsules ...

Journal: :Journal of insurance medicine 2004
William R Finch

This paper provides an overview of rheumatoid disease from the perspective of its impact on mortality. The term, rheumatoid arthritis, may promote the misconception that this disease is relatively trivial and easily managed; therefore, "rheumatoid disease" is preferred. Numerous long-term studies in many settings have established that significant excess mortality is associated with rheumatoid d...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید